Study guide

3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension

AMCB Certified Nurse-Midwife CNM

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care

1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral

2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts

2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy

3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy

3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy

4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss

4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care

5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance

5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion

6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation

6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy

7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair

7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture

8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation

8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications

9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage

9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation

10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health

10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis

11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination

11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes

12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days

12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days

13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization

13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening

14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation

14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral

15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders

15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome

16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause

16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis

17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions

17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking

18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity

18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care

3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension

Key Takeaways Explain This Topic AI

Gestational hypertension and preeclampsia without severe features are delivered at 37 0/7 weeks, while preeclampsia with severe features is delivered at 34 0/7 weeks or immediately if unstable.

Low-dose aspirin 81 to 162 mg daily is started between 12 and 16 weeks for any one high-risk factor or any two moderate-risk factors and continued until delivery.

Blood pressure in hypertensive disorders of pregnancy peaks on postpartum days 3 through 6, after most patients have been discharged.

ACOG recommends postpartum blood pressure evaluation no later than 7 to 10 days after birth, and within 72 hours for patients who had severe-range readings.

A history of preeclampsia roughly doubles lifetime risk of ischemic heart disease and stroke and quadruples heart failure risk, so it belongs on the permanent problem list.

Last updated: September 2026

Delivery Timing and Midwifery Management

Delivery is the definitive cure for preeclampsia, as the placenta is the fundamental source of the circulating antiangiogenic factors (e.g., soluble fms-like tyrosine kinase-1 [sFlt-1] and soluble endoglin) driving widespread maternal endothelial injury. However, delivery timing requires balancing maternal stabilization against the risks of neonatal prematurity.

Delivery Timing Guidelines (ACOG/SMFM Standards)

Gestational Hypertension and Preeclampsia without Severe Features:

Timing: Deliver at 37 0/7 weeks gestation (or upon diagnosis if diagnosed at ≥37 weeks).

Evidence: Expectant management beyond 37 weeks increases the risk of severe preeclampsia, abruption, and cesarean birth without neonatal benefit.

Preeclampsia with Severe Features:

Timing at ≥34 0/7 weeks: Delivery is indicated upon stabilization.

Timing <34 0/7 weeks (Expectant Inpatient Management): In carefully selected, stable patients admitted to a tertiary perinatal center with Level III/IV NICU care, expectant management up to 34 0/7 weeks may be pursued to allow administration of antenatal corticosteroids (betamethasone 12 mg IM q24h x 2 doses) for fetal lung maturity.

Absolute Indications for Immediate Delivery at Any Gestational Age:

  • Uncontrolled severe-range hypertension refractory to dual-agent pharmacotherapy
  • Eclampsia
  • Pulmonary edema
  • Placental abruption
  • Disseminated intravascular coagulation (DIC)
  • Progressive renal failure (doubling of creatinine or acute anuria)
  • Persistent, severe epigastric/RUQ pain with hepatic rupture or subcapsular hematoma
  • Non-reassuring fetal status (Category III FHR tracing or persistent biophysical profile ≤4/10)

Mode of Delivery: Induction of labor for vaginal birth is preferred unless standard obstetric indications for cesarean delivery exist. Cervical ripening (e.g., mechanical with Foley balloon or pharmacologic) should be initiated when the cervix is unfavorable. Cesarean delivery is reserved for fetal distress, failed induction, malpresentation, or catastrophic maternal collapse.

Primary Prevention: Low-Dose Aspirin Prophylaxis

Low-dose aspirin inhibits platelet cyclooxygenase-1 (COX-1), shifting the balance of vasoactive prostanoids away from vasoconstrictive thromboxane A2 and toward vasodilatory prostacyclin (PGI2), thereby improving spiral artery remodeling and placental perfusion.

Target Population:

High-Risk (Recommend Aspirin if ≥1 High-Risk Factor Present):

  • History of preeclampsia, especially early-onset or complicated by adverse outcomes
  • Multifetal gestation
  • Chronic hypertension
  • Pregestational diabetes mellitus (Type 1 or Type 2)
  • Pre-existing renal disease
  • Autoimmune disease (systemic lupus erythematosus, antiphospholipid syndrome)

Moderate-Risk (Consider Aspirin if ≥2 Moderate-Risk Factors Present):

  • Nulliparity
  • Obesity (pre-pregnancy BMI ≥30 kg/m²)
  • Family history of preeclampsia (mother or sister)
  • Advanced maternal age (≥35 years)

Sociodemographic characteristics (e.g., lower socioeconomic status, Black race due to systemic healthcare inequities)

  • Interpregnancy interval >10 years
  • Personal history of small-for-gestational-age infant or prior adverse pregnancy outcome

Dosage and Timing:

Dose: 81 to 162 mg daily (many clinical centers now utilize 162 mg [two 81 mg tablets] daily for higher efficacy).

Initiation: Between 12 and 16 weeks gestation (optimally before 16 weeks; acceptable up to 28 weeks).

Duration: Continued daily until delivery (or discontinued at 36–37 weeks per local clinical protocol).

Postpartum Blood Pressure Surveillance and Long-Term Risk

Delivery removes the placenta, but it does not immediately remove the disease. Blood pressure in hypertensive disorders of pregnancy typically peaks on postpartum days 3 through 6 as extravascular fluid mobilizes back into the intravascular space — after most patients have already gone home.

Surveillance Standards

De novo postpartum preeclampsia and eclampsia can present for the first time up to 6 weeks after birth . Any postpartum patient with a new severe headache, visual change, epigastric pain, or dyspnea needs a blood pressure and a preeclampsia panel, not reassurance.

ACOG recommends a blood pressure evaluation no later than 7 to 10 days postpartum for all hypertensive disorders of pregnancy, and within 72 hours for patients who had severe-range readings. Home blood pressure monitoring with text-based or remote reporting improves follow-up and has been shown to narrow racial disparities in postpartum readmission.

Give every hypertensive patient written return precautions before discharge, naming the specific symptoms and the phone number to call.

Postpartum Pharmacologic Management

Treat severe-range postpartum blood pressure with the same first-line agents used antepartum: IV labetalol, IV hydralazine, or oral immediate-release nifedipine.

For maintenance, extended-release nifedipine and labetalol are both effective and lactation-compatible. Methyldopa is generally avoided postpartum because of its association with depression.

NSAIDs are appropriate postpartum analgesia even in hypertensive patients and are preferred over opioids; current ACOG guidance does not support withholding them on the basis of hypertension alone.

Continue magnesium sulfate for at least 24 hours postpartum in preeclampsia with severe features, eclampsia, and HELLP syndrome.

Lifelong Cardiovascular Implications

A hypertensive disorder of pregnancy is a sex-specific cardiovascular risk factor , not a self-limited obstetric event.

Compared with normotensive pregnancy, a history of preeclampsia confers roughly twice the lifetime risk of ischemic heart disease and stroke and about four times the risk of heart failure .

The ACC/AHA and ACOG recommend that the adverse pregnancy outcome be documented in the permanent problem list and communicated to the primary care clinician, with ongoing blood pressure, lipid, and glucose screening.

Counsel about interpregnancy care : weight and blood pressure optimization, and low-dose aspirin from 12 to 16 weeks in the next pregnancy , since prior preeclampsia is a high-risk indication on its own.